Dianthus Therapeutics (DNTH) Free Cash Flow (2017 - 2025)

Dianthus Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$30.6 million for Q3 2025.

• On a quarterly basis, Free Cash Flow fell 43.53% year-over-year to -$30.6 million in Q3 2025; TTM through Dec 2025 was -$82.2 million, a 4.94% decrease from a year earlier, with the FY2024 full-year figure at -$78.3 million, down 111.75% from the prior year.
• Free Cash Flow retreated to -$30.6 million in Q3 2025 per DNTH's latest filing, from -$23.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $16.4 million in Q3 2022 and bottomed at -$30.6 million in Q3 2025.
• The 5-year median for Free Cash Flow is -$15.2 million (2021), against an average of -$15.1 million.
• Across the five-year window, Free Cash Flow surged 208.05% in 2022 and sank 206.08% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$15.7 million in 2021, then surged by 43.46% to -$8.9 million in 2022, then sank by 33.6% to -$11.9 million in 2023, then tumbled by 131.58% to -$27.5 million in 2024, then retreated by 11.23% to -$30.6 million in 2025.
• Per Business Quant, the three latest DNTH Free Cash Flow figures stand at -$30.6 million (Q3 2025), -$23.9 million (Q2 2025), and -$27.7 million (Q1 2025).